Prenatal cystic fibrosis screening in Mexican Americans: An economic analysis - 28/08/11
Abstract |
Objective |
We evaluated the cost benefit of cystic fibrosis screening in Mexican American gravid women.
Study design |
With the use of decisions analysis techniques, a cost-benefit analysis was performed. Baseline assumptions were based on published references. Sensitivity analyses were performed.
Results |
Under the baseline assumptions, screening was not cost beneficial. Threshold analysis showed that, if the test was priced under $53.00, screening became cost beneficial. Sensitivity analysis demonstrated that lower acceptance rates of amniocentesis or termination made the screening strategy less attractive. If the test sensitivity was raised to 90%, which required testing of >60 mutations, the cost of screening would need to be <$100.00 for the program to be cost beneficial.
Conclusion |
Cystic fibrosis screening is not cost beneficial in Mexican American women over a wide range of assumptions. This is principally due to the poor sensitivity of the test in this population. Cultural factors, such as lower acceptance of amniocentesis and pregnancy termination of affected fetuses, further lower the cost-benefit ratio of screening.
Le texte complet de cet article est disponible en PDF.Keywords : Cystic fibrosis, prenatal screening, cost, Mexican American
Plan
Presented at the Twenty-Third Annual Meeting of the Society for Maternal-Fetal Medicine, San Francisco, Calif, February 3-8, 2003. |
Vol 189 - N° 3
P. 769-774 - septembre 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?